Tevimbra (tislelizumab)

pCPA File Number: 23581

Negotiation Status:

Under consideration for negotiation

Indication(s):

in combination with gemcitabine and platinum chemotherapy, for the first-line treatment of adult patients with recurrent or metastatic nasopharyngeal carcinoma (NPC).

Sponsor/Manufacturer:

BeiGene, Ltd.

CDA-AMC Project Number:

PC0399-000

pCPA Engagement Letter Issued:

Not Applicable

Negotiation Process Concluded:

Not Applicable